The tablet is the most successful dosage form in history. It is also the quiet constraint on what medicine can do next.
A format inherited, not designed
The compressed tablet was not the product of a careful study of the human body. It was an industrial answer to a 19th-century problem — how to turn powder into a stable, shippable object at scale. Nearly two centuries later, almost every oral medicine still takes that same shape, for reasons that have far more to do with manufacturing than with you.
The tablet was never truly chosen. It simply settled — and what settles can be unsettled.
What the tablet quietly enforces
Three assumptions come baked into the format, and we rarely question any of them. The first is that dose must equal mass: need more drug, and the answer is a bigger object to swallow. The second is that absorption must wait on dissolution — the tablet has to break apart and dissolve before any of it can be taken up, which paces and limits every dose. The third is that everyone gets the same rigid unit, regardless of weight, age or how well they absorb.
Each made sense for a production line. None was decided for the patient.
The cost the format hides
A tablet that is hard to swallow is a quiet driver of medicines simply not being taken, and the people who struggle most — the very young, the elderly, anyone with difficulty swallowing — are precisely those who depend on them most. Tie dose to size and you also tie it to waste: more material made, handled and lost for every milligram that actually works.
The point is the format, not the molecule
It is tempting to treat poor performance as a property of the drug. Far more often, it is a property of the form the drug was forced into. Change the form — design for absorption rather than compression, for the body rather than the machine — and a different set of possibilities opens up. That is the question the next generation of drug delivery is built to ask.
Read deeper
- Who Decided How Big a Tablet Should Be? — the hidden engineering behind every pill’s size.
- Pharma Optimised for Factories, Not Humans — how production, not biology, shaped the dosage form.
- Standard Dosing Is Fundamentally Broken — why one fixed unit cannot fit every body.
- The Fixed-Dose Illusion — the false comfort of a single standard dose.
- The Dissolution Trap — how dissolve-then-absorb paces and caps every dose.
- The End of the Tablet Era — the case that the format has reached its limits.
About Ibumix
Ibumix is developing a series of new liquid drug-delivery platforms built on glyceryl caprate (GCC) lipid chemistry — re-engineering how established medicines are delivered, beginning with the NSAID class. Ibuprofen and naproxen are the starting points; the opportunity extends well beyond them.
Sources
- Tablet size and physical attributes; swallowing difficulty and adherence — FDA guidance on the size, shape and other physical attributes of tablets and capsules; dysphagia and medication-adherence literature.
- Origin of the compressed tablet (William Brockedon, 1843) — British Patent, 1843–44; see William Brockedon.
- Dose tied to physical form and the dissolution-paced absorption model — pharmaceutics literature (e.g. Aulton’s Pharmaceutics; BCS framework).
See how this connects to what Ibumix is building: the Mix platform — one architecture, seven chassis.